An observational study in Hepatocellular Carcinoma, sponsored by Rehab Werida. Completed at 1 site in Saudi Arabia. Open to participants aged 20 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-03-28.
Sponsored by Rehab Werida · Observational
The study included 81 HCC patients, both male and female. Prior to being assessed for eligibility, each recruited patient with HCC received a comprehensive review of their medical history, physical status, and laboratory results. Every research participant take part in the experiment and provided written informed consent.
All patients had their baseline viral indicators for HBV and HCV evaluated. Additionally, blood samples were taken for genotyping. All patients underwent evaluations of their kidney, liver, and alpha fetoprotein (AFP) functions, as well as their complete blood count (CBC), at both the baseline and follow-up appointments. To evaluate the efficacy of TACE, triple pelvic abdominal CT scans were performed both prior to and one month later. Using triphasic pelviabdominal CT, patients who achieved complete response (CR) were monitored for up to 13 months following chemotherapy in order to identify recurrence. Follow-up appointments were planned to identify patients responces or any negative effects.
6,741 studies on the registry are indexed under Carcinoma; 1,161 are open to participants now.
This study's enrollment of 81 is below the median of 149 across 1,175 observational studies indexed under Carcinoma.
Browse Carcinoma studies →Rehab Werida is the lead sponsor of 12 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
100 HCC patients, both male and female. Prior to being assessed for eligibility, each recruited patient with HCC received a comprehensive review of their medical history, physical status, and laboratory results.
Exclusion Criteria:
Each of the patients was given Doxorubicin and followed up for one year.
Drug: Doxorubicin
each recruited patient with HCC received a comprehensive review of their medical history, physical status, and laboratory results.
Also known as: Dox
GSTP1
Genotyping
Time frame: 1 year
CYP2B6
Genotyping
Time frame: 1 year
This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Rehab Werida